Stock Comparison
Novartis AG vs Roche Holding AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Novartis AG
NOVN · SIX Swiss Exchange
Weighted across the company's segments.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisRoche Holding AG
ROP · SIX Swiss Exchange (participation certificate)
Weighted across the company's segments.
Full stock profile
Dive deeper into Roche Holding AG's moat claims, evidence, and risks.
View ROP analysisComparison highlights
- Moat score gap: Roche Holding AG leads (69 / 100 vs 56 / 100 for Novartis AG).
- Segment focus: Novartis AG has 5 segments (31% in Oncology); Roche Holding AG has 2 segments (77.8% in Pharmaceuticals).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Novartis AG has 2 moat types across 2 domains; Roche Holding AG has 3 across 2.
Primary market context
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
31%
Roche Holding AG
Pharmaceuticals
Innovative (branded) prescription pharmaceuticals
Global
Healthcare providers and systems (hospitals/clinics), payers/governments, and patients
Innovator pharmaceutical developer, manufacturer and marketer
77.8%
Side-by-side metrics
Moat coverage
Shared moat types
Novartis AG strengths
Roche Holding AG strengths
Segment mix
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Roche Holding AG segments
Full profile >Pharmaceuticals
Competitive
Diagnostics
Oligopoly
Act on this comparison
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.